Literature DB >> 32803709

The Metabolic Effects of Pre-probiotic Supplementation After Roux-en-Y Gastric Bypass (RYGB) Surgery: a Prospective, Randomized Controlled Study.

Fulya Calikoglu1, Umut Barbaros2, Ayse Kubat Uzum3, Yildiz Tutuncu3, Ilhan Satman3.   

Abstract

PURPOSE: Following Roux-en-Y gastric bypass (RYGB), positive alterations are observed in gut microbiota and intestinal peptides. Previous studies demonstrated similar alterations observed in cases when pre-probiotics are used without surgery. The aim of this trial was to evaluate the effectiveness of early use of pre-probiotics after RYGB.
MATERIAL AND METHODS: The operation and follow-up of the patients were performed at Istanbul University Medical Faculty. Thirty-two patients who had undergone RYGB were randomized to pre-probiotic group (PreProBG, n = 16; 200 g/day yogurt plus 10 g/day inulin+oligofructose) and probiotic group (ProBG, n = 16; 200 g/day yogurt only) for 6 months. Blood samples (glucose, insulin, A1c, GLP-1, PYY), anthropometric measurements, and appetite ratings have been evaluated at baseline and 3 (m3) and 6 (m6) months after RYGB.
RESULTS: Initial anthropometric measurements and appetite ratings decreased significantly after surgery and there were no significant differences between the groups. The decrease of area under the curve(insulin) was less and has a positive correlation with the changes in anthropometric measurements in PreProBG. GLP-1 and PYY which increased dramatically after surgery in all patients were higher in PreProBG. But this increase had a negative correlation with the changes in anthropometric measurements during the study.
CONCLUSION: Increased insulin, GLP-1, and PYY secretion was more enhanced by pre-probiotic use in early postoperative period. But this increase not only in anthropometric measurements but also in appetite ratings affects negatively, contrary to expectations. In summary, it should be investigated with new studies that use of pre-probiotics in the late postoperative period may be more effective in patients with weak insulin and incretin response and therefore insufficient weight loss. Trial Registration clinicaltrials.gov Identifier: NCT03517345.

Entities:  

Keywords:  Gastric bypass surgery; Glucagon-like peptide-1; PYY; Prebiotics

Mesh:

Substances:

Year:  2020        PMID: 32803709     DOI: 10.1007/s11695-020-04894-6

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  2 in total

1.  American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient.

Authors:  Jeffrey I Mechanick; Robert F Kushner; Harvey J Sugerman; J Michael Gonzalez-Campoy; Maria L Collazo-Clavell; Adam F Spitz; Caroline M Apovian; Edward H Livingston; Robert Brolin; David B Sarwer; Wendy A Anderson; John Dixon; Safak Guven
Journal:  Obesity (Silver Spring)       Date:  2009-04       Impact factor: 5.002

2.  Obesity and hypertension, heart failure, and coronary heart disease-risk factor, paradox, and recommendations for weight loss.

Authors:  Surya M Artham; Carl J Lavie; Richard V Milani; Hector O Ventura
Journal:  Ochsner J       Date:  2009
  2 in total
  1 in total

Review 1.  Prolonged Isolated Soluble Dietary Fibre Supplementation in Overweight and Obese Patients: A Systematic Review with Meta-Analysis of Randomised Controlled Trials.

Authors:  Valentina V Huwiler; Katja A Schönenberger; Alexander Segesser von Brunegg; Emilie Reber; Stefan Mühlebach; Zeno Stanga; Maria L Balmer
Journal:  Nutrients       Date:  2022-06-24       Impact factor: 6.706

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.